BioMarin Pharmaceuticals
BMRN
391 hedge funds and large institutions have $21.6B invested in BioMarin Pharmaceuticals in 2015 Q2 according to their latest regulatory filings, with 55 funds opening new positions, 155 increasing their positions, 128 reducing their positions, and 40 closing their positions.
38% more first-time investments, than exits
New positions opened: 55 | Existing positions closed: 40
21% more repeat investments, than reductions
Existing positions increased: 155 | Existing positions reduced: 128
12% more call options, than puts
Call options by funds: $329M | Put options by funds: $294M
11% more capital invested
Capital invested by funds: $19.5B → $21.6B (+$2.11B)
4% more funds holding
Funds holding: 377 → 391 (+14)
0% more funds holding in top 10
Funds holding in top 10: 16 → 16 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$245M |
| 2 |
JP Morgan Chase
New York
|
+$146M |
| 3 |
Temasek Holdings
Singapore
|
+$77M |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$70.9M |
| 5 |
Balyasny Asset Management
Chicago,
Illinois
|
+$66.6M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Sands Capital Management
Arlington,
Virginia
|
-$87.7M |
| 2 |
Goldman Sachs
New York
|
-$83.6M |
| 3 |
SC
Sculptor Capital
New York
|
-$74.4M |
| 4 |
VAM
Visium Asset Management
New York
|
-$72.8M |
| 5 |
TG
TCW Group
Los Angeles,
California
|
-$58.8M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OI
426
Oakbrook Investments
Lisle,
Illinois
| – | -$209K | -1,675 | Closed |
|
427
Federated Hermes
Pittsburgh,
Pennsylvania
| – | -$138K | -1,104 | Closed |
|
|
SEC
428
Seven Eight Capital
New York
| – | -$112K | -900 | Closed |
|
|
WAM
429
Wolverine Asset Management
Chicago,
Illinois
| – | -$68.2K | -550 | Closed |
|
|
BCM
430
Blume Capital Management
Berkeley,
California
| – | -$10K | -80 | Closed |
|
|
ZB
431
Zions Bancorporation
Salt Lake City,
Utah
| – | -$3K | -28 | Closed |
|
BMRN Hedge Fund Activity: Q2 2015 in Review
391 of the 3,711 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q2 2015, worth a combined $21.6B — up 11% from $19.5B a quarter earlier.
Buyers outnumbered sellers: 55 funds opened new BMRN positions and 40 closed out — a net gain of 15 holders — while 155 added to existing stakes and 128 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $245M. The largest seller was Sands Capital Management, cutting an estimated $87.7M.
- 391 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q2 2015, up from 377 in Q1 2015.
- Funds reported $21.6B of BioMarin Pharmaceuticals stock for Q2 2015, up 11% quarter-over-quarter.
- 55 funds opened new BioMarin Pharmaceuticals positions in Q2 2015 and 40 closed out, a net change of +15 holders.
- The largest BioMarin Pharmaceuticals buyer in Q2 2015 was Fidelity Investments, an estimated $245M added.
- The largest BioMarin Pharmaceuticals seller in Q2 2015 was Sands Capital Management, an estimated $87.7M sold.
Based on aggregated 13F filings for Q2 2015.